Biokier
1 known investors
BioKier develops oral products for managing lipids and glucose in type 2 diabetes and cardiometabolic disorders, designed to replicate the metabolic benefits of bariatric surgery through colon-targeted nutrient delivery. The company is a clinical-stage biotech pursuing regulatory approval via the 505(b)2 NDA pathway.
BiotechHealthtechMedical Devices